Quince Therapeutics (QNCX) Institutional Ownership $1.66 -0.06 (-3.49%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)CurrentInstitutional OwnershipPercentage30.75%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$51.36KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$27.15K Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNCX Institutional Buying and Selling by Quarter Quince Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024Geode Capital Management LLC339,125$263K0.0%+24.2%0.784% 8/9/2024Renaissance Technologies LLC483,902$363K0.0%-7.0%1.120% 1/12/2024Scharf Investments LLC91,061$96K0.0%N/A0.212% 7/31/2023Intellectus Partners LLC53,527$81K0.0%N/A0.148% 7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892% 5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642% 4/20/2023 Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086% (Data available from 1/1/2016 forward) QNCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNCX shares? During the previous two years, the following institutional investors and hedge funds held shares of Quince Therapeutics shares: BML Capital Management LLC ($2.13M), EPIQ Capital Group LLC ($1.50M), Renaissance Technologies LLC ($363K), Geode Capital Management LLC ($263K), Scharf Investments LLC ($96K), and Intellectus Partners LLC ($81K), and Hennion & Walsh Asset Management Inc. ($48K).Learn more on QNCX's institutional investors. What percentage of Quince Therapeutics stock is owned by institutional investors? 30.75% of Quince Therapeutics stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings. Which institutional investors have been buying Quince Therapeutics stock? The following institutional investors have purchased Quince Therapeutics stock in the last 24 months: BML Capital Management LLC ($1.41M), Scharf Investments LLC ($91.06K), Geode Capital Management LLC ($66.17K), Intellectus Partners LLC ($53.53K), and Hennion & Walsh Asset Management Inc. ($31.06K). How much institutional buying is happening at Quince Therapeutics? Institutional investors have bought a total of 1,653,658 shares in the last 24 months. This purchase volume represents approximately $2.40M in transactions. Which Quince Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Quince Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($97.72K), and Renaissance Technologies LLC ($36.20K). How much institutional selling is happening at Quince Therapeutics? Institutional investors have sold a total of 133,920 shares in the last 24 months. This volume of shares sold represents approximately $179.59K in transactions. Related Companies Tango Therapeutics Major Shareholders Trevi Therapeutics Major Shareholders Chimerix Major Shareholders SNDL Major Shareholders biote Major Shareholders Voyager Therapeutics Major Shareholders iTeos Therapeutics Major Shareholders LifeVantage Major Shareholders Aquestive Therapeutics Major Shareholders Immutep Major Shareholders This page (NASDAQ:QNCX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.